Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 167
Filtrar
Más filtros

Banco de datos
Tipo del documento
Intervalo de año de publicación
1.
J Appl Biomed ; 21(2): 59-66, 2023 06.
Artículo en Inglés | MEDLINE | ID: mdl-37376882

RESUMEN

BACKGROUND: The core motive of pharmacovigilance is the detection and prevention of adverse drug reactions (ADRs), to improve the risk-benefit balance of the drug. However, the causality assessment of ADRs remains a major challenge among clinicians, and none of the available tools of causality assessment used for assessing ADRs have been universally accepted. OBJECTIVE: To provide an up-to-date overview of the different causality assessment tools. METHODS: We conducted electronic searches in MEDLINE, EMBASE, and the Cochrane database. The eligibility of each tool was screened by three reviewers. Each eligible tool was then scrutinized for its domains (the reported specific set of questions/areas used for calculating the likelihood of cause-and-effect relation of an ADR) to discover the most comprehensive tool. Finally, we subjectively assessed the tool's ease-of-use in a Canadian, Indian, Hungarian, and Brazilian clinical context. RESULTS: Twenty-one eligible causality assessment tools were retrieved. Naranjo's tool and De Boer's tool appeared the most comprehensive among all the tools, covering 10 domains each. Regarding "ease-of-use" in a clinical setting, we judged that many tools were hard to implement in a clinical context because of their complexity and/or lengthiness. Naranjo's tool, Jones's tool, Danan and Benichou's tool, and Hsu and Stoll's tool appeared to be the easiest to implement into various clinical contexts. CONCLUSION: Among the many tools identified, 1981 Naranjo's scale remains the most comprehensive and easy to use for performing causality assessment of ADRs. Upcoming analysis should compare the performance of each ADR tool in clinical settings.


Asunto(s)
Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos , Farmacovigilancia , Humanos , Canadá , Medición de Riesgo , Probabilidad , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/diagnóstico , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/epidemiología , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/prevención & control
2.
Hum Mol Genet ; 28(3): 372-385, 2019 02 01.
Artículo en Inglés | MEDLINE | ID: mdl-30239726

RESUMEN

Children conceived using Assisted Reproductive Technologies (ART) have a higher incidence of growth and birth defects, attributable in part to epigenetic perturbations. Both ART and germline defects associated with parental infertility could interfere with epigenetic reprogramming events in germ cells or early embryos. Mouse models indicate that the placenta is more susceptible to the induction of epigenetic abnormalities than the embryo, and thus the placental methylome may provide a sensitive indicator of 'at risk' conceptuses. Our goal was to use genome-wide profiling to examine the extent of epigenetic abnormalities in matched placentas from an ART/infertility group and control singleton pregnancies (n = 44/group) from a human prospective longitudinal birth cohort, the Design, Develop, Discover (3D) Study. Principal component analysis revealed a group of ART outliers. The ART outlier group was enriched for females and a subset of placentas showing loss of methylation of several imprinted genes including GNAS, SGCE, KCNQT1OT1 and BLCAP/NNAT. Within the ART group, placentas from pregnancies conceived with in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI) showed distinct epigenetic profiles as compared to those conceived with less invasive procedures (ovulation induction, intrauterine insemination). Male factor infertility and paternal age further differentiated the IVF/ICSI group, suggesting an interaction of infertility and techniques in perturbing the placental epigenome. Together, the results suggest that the human placenta is sensitive to the induction of epigenetic defects by ART and/or infertility, and we stress the importance of considering both sex and paternal factors and that some but not all ART conceptuses will be susceptible.


Asunto(s)
Placenta/fisiología , Placentación/genética , Técnicas Reproductivas Asistidas/efectos adversos , Adulto , Estudios de Cohortes , ADN/metabolismo , Metilación de ADN/genética , Epigénesis Genética/genética , Epigenómica , Femenino , Fertilización In Vitro/efectos adversos , Estudio de Asociación del Genoma Completo/métodos , Impresión Genómica/genética , Humanos , Lactante , Recién Nacido , Infertilidad Masculina/metabolismo , Estudios Longitudinales , Masculino , Persona de Mediana Edad , Modelos Animales , Inducción de la Ovulación/efectos adversos , Placenta/metabolismo , Embarazo , Análisis de Componente Principal , Estudios Prospectivos , Reproducción , Inyecciones de Esperma Intracitoplasmáticas/efectos adversos
3.
BMC Pregnancy Childbirth ; 21(1): 800, 2021 Dec 01.
Artículo en Inglés | MEDLINE | ID: mdl-34847870

RESUMEN

BACKGROUND: Recent studies show a rapid growth among pregnant women using high potency opioids for common pain management during their pregnancy. No study has examined the duration of treatment among strong opioid users and weak opioid users during pregnancy. We aimed to investigate the prevalence of prescribed opioid use during pregnancy, in Quebec; and to compare the duration of opioid treatment between strong opioid users and weak opioid users. METHODS: Using the Quebec Pregnancy Cohort (1998-2015), we included all pregnancies covered by the Quebec Public Prescription Drug Insurance Program. Opioid exposure was defined as filled at least one prescription for any opioid during pregnancy or before pregnancy but with a duration that overlapped the beginning of pregnancy. Prevalence of opioids use was calculated for all pregnancies, according to pregnancy outcome, trimester of exposure, and individual opioids. The duration of opioid use during pregnancy was analyzed according to 8 categories based on cumulative duration (< 90 days vs. ≥90 days), duration of action (short-acting vs. long-acting) and strength of the opioid (weak vs. strong). RESULTS: Of 442,079 eligible pregnancies, 20,921 (4.7%) were exposed to opioids. Among pregnancies ending with deliveries (n = 249,234), 5.4% were exposed to opioids; the prevalence increased by 40.3% from 3.9% in 1998 to 5.5% in 2015, more specifically a significant increase in the second and third trimesters of pregnancy. Weak opioid, codeine was the most commonly dispensed opioid (70% of all dispensed opioids), followed by strong opioid, hydromorphone (11%), morphine (10%), and oxycodone (5%). The prevalence of codeine use decreased by 47% from 4.3% in 2005 to 2.3% in 2015, accompanied by an increased use of strong opioid, morphine (0.029 to 1.41%), hydromorphone (0.115 to 1.08%) and oxycodone (0.022 to 0.44%), from 1998 to 2015. The average durations of opioid exposure were significantly longer among pregnancies exposed to strong opioid as compared to weak opioid regardless of the cumulative duration or duration of action (P < 0.05). CONCLUSIONS: Given the differences in the safety profile between strong opioids and the major weak opioid codeine, the increased use of strong opioids during pregnancy with longer treatment duration raises public health concerns.


Asunto(s)
Analgésicos Opioides/uso terapéutico , Duración de la Terapia , Mujeres Embarazadas , Medicamentos bajo Prescripción/uso terapéutico , Estudios de Cohortes , Femenino , Humanos , Embarazo , Resultado del Embarazo/epidemiología , Prevalencia , Quebec/epidemiología
4.
CMAJ ; 191(7): E179-E187, 2019 02 19.
Artículo en Inglés | MEDLINE | ID: mdl-30782643

RESUMEN

BACKGROUND: While topical azoles are the first-line treatment for fungal infections, oral fluconazole is frequently used during pregnancy. We aimed to assess the effect of exposure to low and high doses of fluconazole during pregnancy on the occurrence of spontaneous abortions, major congenital malformations and stillbirths. METHODS: Within the Quebec Pregnancy Cohort (1998-2015), we identified women exposed to low- (≤ 150 mg) and high-dose (> 150 mg) fluconazole, and women who were not exposed. For each case of spontaneous abortion or stillbirth, up to 5 controls were randomly selected using an incidence density sampling method matched on gestational age at diagnosis of spontaneous abortion or stillbirth (index date) and the year of the last menstrual period. For cases of major congenital malformation, we considered all liveborn babies as controls. Generalized estimation equation models were used to analyze the 3 main outcomes separately. RESULTS: Within a cohort of 441 949 pregnancies, 320 868 pregnancies were included in the analyses of spontaneous abortions, 226 599 of major congenital malformations and 7832 of stillbirths. Most (69.5%) women exposed to fluconazole in pregnancy received the common single therapeutic dose of 150 mg (low dose); the remainder received a dose of > 150 mg (high dose). Use of oral fluconazole during early pregnancy was associated with an increased risk of spontaneous abortion compared with no exposure (adjusted odds ratio [OR] for 345 cases exposed to low-dose treatment 2.23, 95% confidence interval [CI] 1.96-2.54; adjusted OR for 249 cases exposed to high-dose treatment 3.20, 95% CI 2.73-3.75). Exposure to fluconazole during the first trimester did not increase the risk of overall major congenital malformations; however, exposure to a high dose during the first trimester was associated with an increased risk of cardiac septal closure anomalies (adjusted OR 1.81, 95% CI 1.04-3.14; 13 exposed cases) compared with no exposure. No association was found between exposure to fluconazole during pregnancy and the risk of stillbirth. INTERPRETATION: Any maternal exposure to fluconazole during pregnancy may increase risk of spontaneous abortion and doses higher than 150 mg during the first trimester may increase risk of cardiac septal closure anomalies.


Asunto(s)
Aborto Espontáneo/inducido químicamente , Antifúngicos/efectos adversos , Fluconazol/efectos adversos , Defectos de los Tabiques Cardíacos/inducido químicamente , Exposición Materna/efectos adversos , Mortinato/epidemiología , Aborto Espontáneo/epidemiología , Administración Oral , Adolescente , Adulto , Antifúngicos/administración & dosificación , Candidiasis Vulvovaginal/tratamiento farmacológico , Estudios de Casos y Controles , Estudios de Cohortes , Femenino , Fluconazol/administración & dosificación , Edad Gestacional , Defectos de los Tabiques Cardíacos/epidemiología , Humanos , Modelos Logísticos , Análisis Multivariante , Embarazo , Complicaciones Infecciosas del Embarazo/tratamiento farmacológico , Primer Trimestre del Embarazo , Quebec/epidemiología , Adulto Joven
5.
Ann Rheum Dis ; 77(4): 500-509, 2018 04.
Artículo en Inglés | MEDLINE | ID: mdl-29222350

RESUMEN

OBJECTIVES: Leflunomide is known to be embryotoxic and teratogenic in rodents. However, there is less evidence in humans. We quantified the risk of major congenital malformation (MCM), prematurity, low birth weight (LBW) and spontaneous abortion associated with leflunomide exposure during pregnancy in humans. METHODS: From a cohort of 289 688 pregnancies in Montreal, Quebec, Canada, from 1998 to 2015, first-trimester leflunomide exposure and other antirheumatic drug exposures were studied for their association with MCM and spontaneous abortions. Also second or third-trimester leflunomide exposures were examined for associations with prematurity and LBW. Logistic regression model-based generalised estimating equations were used. RESULTS: 51 pregnancies were exposed to leflunomide during the first trimester, and 21 during the second/third trimesters. Adjusting for potential confounders, use of leflunomide during the first trimester of pregnancy was not associated with the risk of MCM (adjusted OR (aOR) 0.97, 95% CI 0.81 to 1.16; 5 exposed cases). No association was found between second/third-trimester exposure to leflunomide and the risk of prematurity (aOR 4.03, 95% CI 0.91 to 17.85; 7 exposed cases) nor LBW (aOR 1.06, 95%CI 0.90 to 1.25; 8 exposed cases). Pregnancy exposure to leflunomide was also not associated with the risk of spontaneous abortion (aOR 1.09, 95% CI 0.90 to 1.32; 11 exposed cases). CONCLUSIONS: Maternal exposure to leflunomide during pregnancy was not associated with statistically significant increased risk of MCMs, prematurity, LBW or spontaneous abortions. However, given that relatively few women were exposed to leflunomide during pregnancy in this cohort, caution remains warranted.


Asunto(s)
Anomalías Inducidas por Medicamentos/etiología , Antirreumáticos/efectos adversos , Leflunamida/efectos adversos , Exposición Materna/efectos adversos , Complicaciones del Embarazo/tratamiento farmacológico , Anomalías Inducidas por Medicamentos/epidemiología , Aborto Espontáneo/inducido químicamente , Aborto Espontáneo/epidemiología , Adulto , Femenino , Humanos , Recién Nacido de Bajo Peso , Recién Nacido , Modelos Logísticos , Embarazo , Resultado del Embarazo , Trimestres del Embarazo , Nacimiento Prematuro/inducido químicamente , Nacimiento Prematuro/epidemiología , Estudios Prospectivos , Quebec/epidemiología , Enfermedades Reumáticas/tratamiento farmacológico , Factores de Riesgo , Adulto Joven
6.
Br J Clin Pharmacol ; 84(6): 1198-1205, 2018 06.
Artículo en Inglés | MEDLINE | ID: mdl-29424001

RESUMEN

AIMS: Data available on the fetal safety of trimethoprim-sulfamethoxazole (TMP-SMX) exposure during pregnancy remains scarce and inconclusive. A previous study assessing the link between TMP-SMX exposure during pregnancy and the risk of spontaneous abortion (SA) did not control for protopathic bias and indication bias. METHODS: We conducted a nested control study (n = 77 429 pregnancies including 7039 cases of SA and 70 390 controls) within the Quebec Pregnancy Cohort. For each case of SA, we selected 10 controls at the index date that were matched on gestational age and year of pregnancy. TMP-SMX exposure was defined as either having filled at least one prescription between the first day of gestation (1DG) and the index date, or as having filled a prescription before pregnancy but with a duration overlapping the 1DG (102 pregnancies exposed to TMP-SMX, including 25 cases of SA and 77 controls). RESULTS: Adjusting for potential confounders, TMP-SMX exposure was associated with an increased risk of SA (AOR 2.94, 95% C 1.89-4.57, 25 exposed cases). Similar results were found after controlling for indication bias and protopathic bias. CONCLUSION: Given that this drug is widely use in HIV patients to prevent opportunistic infections and malaria, there is an urgent need to identify potential data sources in Africa for analysis of early pregnancy exposure to TMP-SMX.


Asunto(s)
Aborto Espontáneo/inducido químicamente , Antibacterianos/efectos adversos , Complicaciones Infecciosas del Embarazo/tratamiento farmacológico , Sulfadoxina/efectos adversos , Trimetoprim/efectos adversos , Adolescente , Adulto , Antibacterianos/administración & dosificación , Estudios de Casos y Controles , Combinación de Medicamentos , Femenino , Edad Gestacional , Humanos , Persona de Mediana Edad , Embarazo , Complicaciones Infecciosas del Embarazo/diagnóstico , Complicaciones Infecciosas del Embarazo/microbiología , Quebec , Medición de Riesgo , Factores de Riesgo , Sulfadoxina/administración & dosificación , Resultado del Tratamiento , Trimetoprim/administración & dosificación , Adulto Joven
7.
Rheumatology (Oxford) ; 56(8): 1378-1385, 2017 08 01.
Artículo en Inglés | MEDLINE | ID: mdl-28460079

RESUMEN

Objective: The aim was to evaluate the prevalence of postpartum complications, including depression, in new mothers who had juvenile idiopathic arthritis (JIA) and to assess whether these differ from mothers who never had JIA. Methods: Our cohort study used data from physician billing and hospitalizations covering Quebec, Canada. We identified females with JIA with a first-time birth between 1 January 1983 and 31 December 2010 and assembled a control cohort of first-time mothers without JIA from the same administrative data, matching 4:1 for date of first birth, maternal age and area of residence. We compared the following postpartum complications: major puerperal infection, anaesthetic complications, postpartum haemorrhage, thromboembolism, obstetrical trauma, complications of obstetrical surgical wounds and maternal depression in the first year after delivery, in the JIA vs non-JIA groups, using bivariate analysis and multiple logistic regression. Results: The mean age at delivery was 24.7 years in the JIA group (n = 1681) and 25.0 years for the non-JIA group (n = 6724). Mothers with JIA were more likely to experience complications attributable to anaesthetic [adjusted risk ratio (aRR) 2.17, 95% CI; 1.05, 4.48], postpartum haemorrhage (aRR = 2.75, 95% CI: 2.42, 3.11) and thromboembolism (aRR = 5.27, 95% CI: 1.83, 15.17) but were at lower risk for obstetrical trauma (aRR = 0.78, 95% CI: 0.64, 0.95) or newly to develop depression in the first year postpartum (aRR = 0.52, 95% CI: 0.40, 0.68). Conclusion: Mothers with JIA appear to be at higher risk for complications attributable to anaesthesia, postpartum haemorrhage and thromboembolism. Prevention strategies for postpartum haemorrhage and thromboembolism may be especially important in this population.


Asunto(s)
Artritis Juvenil/complicaciones , Complicaciones del Trabajo de Parto/etiología , Trastornos Puerperales/etiología , Adulto , Anestesia/efectos adversos , Estudios de Casos y Controles , Estudios de Cohortes , Depresión Posparto/etiología , Femenino , Humanos , Modelos Logísticos , Hemorragia Posparto/etiología , Periodo Posparto , Embarazo , Quebec , Factores de Riesgo , Tromboembolia/etiología , Adulto Joven
8.
Br J Clin Pharmacol ; 83(11): 2557-2571, 2017 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-28722171

RESUMEN

AIMS: Few studies have investigated the link between individual antibiotics and major congenital malformations (MCMs) including specific malformations owing to small sample size. We aimed to quantify the association between exposure to gestational antibiotic and the risk of MCMs. METHODS: Using the Quebec pregnancy cohort (1998-2008), we included a total of 139 938 liveborn singleton alive whose mothers were covered by the "Régie de l'assurance maladie du Québec" drug plan for at least 12 months before and during pregnancy. Antibiotic exposure was assessed in the first trimester and MCMs were identified within the first year of life. RESULTS: After adjusting for potential confounders, clindamycin exposure was associated with an increased risk of MCMs (aOR 1.34, 95% CI 1.02-1.77, 60 exposed cases), musculoskeletal system malformations (aOR 1.67, 95% CI 1.12-2.48, 29 exposed cases) and ventricular/atrial septal defect (aOR 1.81, 95% CI 1.04-3.16, 13 exposed cases). Doxycycline exposure increased the risk of circulatory system malformation, cardiac malformations and ventricular/atrial septal defect (aOR 2.38, 95% CI 1.21-4.67, 9 exposed cases; aOR 2.46, 95% CI 1.21-4.99, 8 exposed cases; aOR 3.19, 95% CI 1.57-6.48, 8 exposed cases, respectively). Additional associations were seen with quinolone (1 defect), moxifloxacin (1 defect), ofloxacin (1 defect), macrolide (1 defect), erythromycin (1 defect) and phenoxymethylpenicillin (1 defect). No link was observed with amoxicillin, cephalosporins and nitrofurantoin. Similar results were found when penicillins were used as the comparator group. CONCLUSIONS: Clindamycin, doxycycline, quinolones, macrolides and phenoxymethylpenicillin in utero exposure were linked to organ-specific malformations. Amoxicillin, cephalosporins and nitrofurantoin were not associated with MCMs.


Asunto(s)
Anomalías Inducidas por Medicamentos/epidemiología , Antibacterianos/efectos adversos , Farmacoepidemiología/estadística & datos numéricos , Primer Trimestre del Embarazo/efectos de los fármacos , Anomalías Inducidas por Medicamentos/etiología , Adulto , Estudios de Cohortes , Femenino , Humanos , Lactante , Recién Nacido , Embarazo , Quebec/epidemiología , Factores de Riesgo , Adulto Joven
9.
Br J Clin Pharmacol ; 83(5): 1126-1133, 2017 05.
Artículo en Inglés | MEDLINE | ID: mdl-27874994

RESUMEN

AIM: The use of selective serotonin reuptake inhibitors (SSRIs) in late pregnancy may be associated with an increased risk of persistent pulmonary hypertension of the newborn (PPHN). Limited data are available on the risk of PPHN associated with serotonin norepinephrine reuptake inhibitors (SNRIs). We aimed to quantify both associations. METHODS: Using data from the Quebec Pregnancy Cohort between 1998 and 2009, we included women covered by the provincial drug plan who had a singleton live birth. Exposure categories were SSRI, SNRI and other antidepressant use; non-users were considered as the reference category. Generalized estimating equation models were used to obtain risk estimates and 95% confidence intervals (CIs). Confounding by indication was minimized by adjusting for history of maternal depression/anxiety before pregnancy. RESULTS: Overall, 143 281 pregnancies were included; PPHN was identified in 0.2% of newborns. Adjusting for maternal depression, and other potential confounders, SSRI use during the second half of pregnancy was associated with an increased risk of PPHN [adjusted odds ratio (aOR) 4.29, 95% CI 1.34, 13.77] compared with non-use of antidepressants; SNRI use during the same time window was not statistically associated with the risk of PPHN (aOR 0.59, 95% CI 0.06, 5.62). Use of SSRIs and SNRIs before the 20th week of gestation was not associated with the risk of PPHN. CONCLUSIONS: Use of SSRIs in the second half of pregnancy was associated with the risk of PPHN. Given our results on SNRIs and the lack of statistical power for these analyses, it is unclear whether SNRI use during pregnancy also increases the risk of PPHN.


Asunto(s)
Antidepresivos/efectos adversos , Síndrome de Circulación Fetal Persistente/inducido químicamente , Inhibidores Selectivos de la Recaptación de Serotonina/efectos adversos , Inhibidores de Captación de Serotonina y Norepinefrina/efectos adversos , Adulto , Antidepresivos/administración & dosificación , Estudios de Cohortes , Femenino , Humanos , Recién Nacido , Masculino , Síndrome de Circulación Fetal Persistente/epidemiología , Embarazo , Complicaciones del Embarazo/tratamiento farmacológico , Trimestres del Embarazo , Quebec , Sistema de Registros , Inhibidores Selectivos de la Recaptación de Serotonina/administración & dosificación , Inhibidores de Captación de Serotonina y Norepinefrina/administración & dosificación , Adulto Joven
10.
CMAJ ; 189(17): E625-E633, 2017 May 01.
Artículo en Inglés | MEDLINE | ID: mdl-28461374

RESUMEN

BACKGROUND: Although antibiotics are widely used during pregnancy, evidence regarding their fetal safety remains limited. Our aim was to quantify the association between antibiotic exposure during pregnancy and risk of spontaneous abortion. METHODS: We conducted a nested case-control study within the Quebec Pregnancy Cohort (1998-2009). We excluded planned abortions and pregnancies exposed to fetotoxic drugs. Spontaneous abortion was defined as having a diagnosis or procedure related to spontaneous abortion before the 20th week of pregnancy. The index date was defined as the calendar date of the spontaneous abortion. Ten controls per case were randomly selected and matched by gestational age and year of pregnancy. Use of antibiotics was defined by filled prescriptions between the first day of gestation and the index date and was compared with (a) non-exposure and (b) exposure to penicillins or cephalosporins. We studied type of antibiotics separately using the same comparator groups. RESULTS: After adjustment for potential confounders, use of azithromycin (adjusted odds ratio [OR] 1.65, 95% confidence interval [CI] 1.34-2.02; 110 exposed cases), clarithromycin (adjusted OR 2.35, 95% CI 1.90-2.91; 111 exposed cases), metronidazole (adjusted OR 1.70, 95% CI 1.27-2.26; 53 exposed cases), sulfonamides (adjusted OR 2.01, 95% CI 1.36-2.97; 30 exposed cases), tetracyclines (adjusted OR 2.59, 95% CI 1.97-3.41; 67 exposed cases) and quinolones (adjusted OR 2.72, 95% CI 2.27-3.27; 160 exposed cases) was associated with an increased risk of spontaneous abortion. Similar results were found when we used penicillins or cephalosporins as the comparator group. INTERPRETATION: After adjustment for potential confounders, use of macro-lides (excluding erythromycin), quinolones, tetracyclines, sulfonamides and metronidazole during early pregnancy was associated with an increased risk of spontaneous abortion. Our findings may be of use to policy-makers to update guidelines for the treatment of infections during pregnancy.


Asunto(s)
Aborto Espontáneo/epidemiología , Antibacterianos/efectos adversos , Exposición Materna/efectos adversos , Complicaciones Infecciosas del Embarazo/tratamiento farmacológico , Aborto Espontáneo/inducido químicamente , Adolescente , Adulto , Estudios de Casos y Controles , Estudios de Cohortes , Bases de Datos Factuales , Femenino , Edad Gestacional , Humanos , Macrólidos/efectos adversos , Metronidazol/efectos adversos , Oportunidad Relativa , Embarazo , Quebec , Quinolonas/efectos adversos , Medición de Riesgo , Factores de Riesgo , Sulfonamidas/efectos adversos , Tetraciclinas/efectos adversos , Adulto Joven
11.
Paediatr Perinat Epidemiol ; 31(4): 363-373, 2017 07.
Artículo en Inglés | MEDLINE | ID: mdl-28640459

RESUMEN

BACKGROUND: The association between antidepressant (AD) use during pregnancy and the risk of attention deficit with or without hyperactivity disorder (ADHD) in children is debated. We investigated the risk of ADHD associated with overall and class-specific antidepressant exposure in utero. METHODS: We designed a register-based cohort study using the Quebec Pregnancy/Children Cohort (QPC). A total of 144 406 singleton full-term live-born from 1998 to 2009 were included. Cox proportional hazards regression models were used to estimate unadjusted and adjusted hazard ratio with 95% confidence interval (CI). RESULTS: During 542 897 person-years of follow-up, 4564 (3.2%) infants were identified with ADHD. The mean age at first ADHD diagnosis was 6.3 ± 2.3 years (range 0-11 years), and the mean age at first ADHD medication use was 7.0 ± 1.5 years. Adjusting for potential confounders, including maternal history of depression/anxiety and ADHD, AD use during the 2nd or 3rd trimester of pregnancy was associated with an increased risk of (HR 1.3, 95% CI 1.0, 1.6; 134 exposed cases). More specifically, tricyclic use was associated with an increased risk of ADHD (HR 1.8, 95% CI 1.0, 3.1; 16 exposed cases); SSRI and SNRI use were not associated with increased ADHD risk. CONCLUSION: This study suggests that AD use during the 2nd and 3rd trimester of pregnancy, specifically tricyclics, is an independent risk factor for ADHD in children above and beyond the risk associated with maternal depression/anxiety or ADHD. However, residual confounding by indication severity could not be completely ruled out.


Asunto(s)
Antidepresivos/efectos adversos , Trastorno por Déficit de Atención con Hiperactividad/etiología , Efectos Tardíos de la Exposición Prenatal/epidemiología , Adulto , Trastorno por Déficit de Atención con Hiperactividad/epidemiología , Niño , Preescolar , Depresión/complicaciones , Depresión/tratamiento farmacológico , Femenino , Humanos , Lactante , Recién Nacido , Embarazo , Complicaciones del Embarazo/tratamiento farmacológico , Complicaciones del Embarazo/psicología , Trimestres del Embarazo , Modelos de Riesgos Proporcionales , Quebec/epidemiología , Factores de Riesgo
12.
J Allergy Clin Immunol ; 138(1): 97-104.e7, 2016 07.
Artículo en Inglés | MEDLINE | ID: mdl-27045580

RESUMEN

BACKGROUND: Intranasal corticosteroid use during pregnancy has increased over the past decade. OBJECTIVE: We aim to estimate the safety of intranasal triamcinolone use during pregnancy, which was introduced for over-the-counter use in October 2013. METHODS: We designed a population-based prospective cohort study. From a cohort of 289,723 pregnancies in Montreal, Quebec, Canada, from 1998-2008, intranasal triamcinolone-exposed, other intranasal corticosteroid-exposed, and nonexposed women during the first trimester were studied for major congenital malformations (overall and organ specific) and spontaneous abortions and during the second/third trimesters for small-for-gestational age (SGA) newborns. The first trimester is the time window of interest for malformations and spontaneous abortion (organogenesis), and the second/third trimesters are the time windows of interest for SGA (fetal growth). Logistic regression model-based generalized estimating equations were used. RESULTS: Adjusting for potential confounders, use of intranasal triamcinolone during the first trimester of pregnancy was not significantly associated with the risk of overall congenital malformations (odds ratio [OR], 0.88; 95% CI, 0.60-1.28; 31 exposed cases) compared with nonexposure; however, it was associated with the risk of respiratory defects (OR, 2.71; 95% CI, 1.11-6.64; 5 exposed cases). Pregnancy exposure to intranasal triamcinolone was not significantly associated with the risk of spontaneous abortion (OR, 1.04; 95% CI, 0.76-1.43; 50 exposed cases). No association was found between second- or third-trimester exposure to intranasal triamcinolone and the risk of SGA (OR, 1.06; 95% CI, 0.79-1.43; 50 exposed cases). CONCLUSIONS: Maternal exposure to intranasal triamcinolone during pregnancy was not associated with the risk of SGA/spontaneous abortions/overall malformations. However, it has been shown to increase the risk of respiratory system defects. Chance finding cannot be ruled out.


Asunto(s)
Antiinflamatorios/efectos adversos , Glucocorticoides/efectos adversos , Exposición Materna/efectos adversos , Resultado del Embarazo , Vigilancia en Salud Pública , Triamcinolona/efectos adversos , Aborto Espontáneo/epidemiología , Aborto Espontáneo/etiología , Administración Intranasal , Adulto , Antiinflamatorios/administración & dosificación , Canadá/epidemiología , Comorbilidad , Anomalías Congénitas/epidemiología , Anomalías Congénitas/etiología , Femenino , Glucocorticoides/administración & dosificación , Humanos , Recién Nacido Pequeño para la Edad Gestacional , Estudios Longitudinales , Oportunidad Relativa , Embarazo , Factores de Riesgo , Triamcinolona/administración & dosificación , Adulto Joven
13.
Am J Obstet Gynecol ; 215(5): 611.e1-611.e8, 2016 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-27402053

RESUMEN

BACKGROUND: Smoking during pregnancy is a modifiable risk factor associated with adverse pregnancy outcomes. Smoking during pregnancy has been shown to increase the risk of spontaneous abortion, prematurity, low birthweight, congenital malformations, and sudden infant death syndrome. Despite the fact that it is well known that smoking can lead to adverse pregnancy outcomes, 13-25% of pregnant women overall continue to smoke during this critical period. OBJECTIVE: The objective of the study was to evaluate the effect of gestational use of bupropion and nicotine patch replacement therapy on the risk of the following: (1) smoking cessation, (2) prematurity, and (3) small for gestational age. STUDY DESIGN: Women included in the Quebec Pregnancy Cohort who filled the annual autoadministered questionnaire between Jan. 1, 1998, and June 30, 2009, were studied. Smokers before gestation with a pregnancy resulting in a live birth comprised the study population. Three mutually exclusive study groups were formed among those who smoked at the beginning of pregnancy: gestational users of nicotine patch replacement therapy, bupropion, and smokers who did not use nicotine patch replacement therapy or bupropion. Rate of smoking cessation during pregnancy as well as the risk of prematurity and small for gestational age were studied. RESULTS: Of the 1288 women who met inclusion criteria, 900 were smokers, 72 were bupropion users, and 316 were nicotine patch replacement therapy users. Bupropion and nicotine patch replacement therapy use during pregnancy were associated with higher rates of smoking cessation: 81% in the bupropion group; 79% for nicotine patch replacement therapy; and 0% in those not using buproprion or nicotine patch replacement therapy. After discontinuing smoking cessation medications, 60% of bupropion users and 68% of nicotine patch replacement therapy users did not smoke again during and after pregnancy. Adjusting for potential confounders, nicotine patch replacement therapy use was associated with a lower risk of prematurity (adjusted odds ratio, 0.21, 95% confidence interval, 0.13-0.34), and small-for-gestational-age (adjusted odds ratio, 0.61, 95% confidence interval, 0.41-0.90) compared to smoking. Bupropion was associated with a lower risk of prematurity only (adjusted odds ratio, 0.12, 95% confidence interval, 0.03-0.50). CONCLUSION: Bupropion and nicotine patch replacement therapy have an impact on smoking cessation during and after pregnancy. Nicotine patch replacement therapy also decreased the risk of prematurity and small for gestational age.


Asunto(s)
Bupropión/uso terapéutico , Inhibidores de Captación de Dopamina/uso terapéutico , Nicotina/uso terapéutico , Atención Prenatal/métodos , Cese del Hábito de Fumar/métodos , Dispositivos para Dejar de Fumar Tabaco , Adolescente , Adulto , Femenino , Humanos , Recién Nacido , Recien Nacido Prematuro , Recién Nacido Pequeño para la Edad Gestacional , Estudios Longitudinales , Masculino , Persona de Mediana Edad , Embarazo , Resultado del Embarazo , Nacimiento Prematuro/etiología , Nacimiento Prematuro/prevención & control , Estudios Retrospectivos , Factores de Riesgo , Cese del Hábito de Fumar/estadística & datos numéricos , Adulto Joven
14.
Birth Defects Res A Clin Mol Teratol ; 106(12): 1044-1055, 2016 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-27384265

RESUMEN

BACKGROUND: Human studies are inconsistent with respect to an association between treatment with selective serotonin and serotonin-norepinephrine reuptake inhibitors (SSRI/SNRIs) and an increase in the incidence of congenital heart defects. Here we tested the hypothesis that in utero exposure to venlafaxine, a highly prescribed SNRI, increases the incidence of fetal heart defects and alters placental and fetal heart serotonin signaling in the rat. METHODS: Timed-pregnant Sprague Dawley rats were gavaged daily with venlafaxine hydrochloride (0, 3, 10, 30, or 100 mg/kg/day) from gestation day 8 to 20. On gestation day 21, fetuses were examined for external and internal malformations; placentas and fetal hearts were collected for the analysis of gene expression. RESULTS: Venlafaxine had no effect on the number of live fetuses, fetal body weights, or external morphology in the absence of maternal toxicity. However, venlafaxine significantly increased the placental index (fetal body/placental weight ratio) and the incidence of fetal cardiac anomalies. Venlafaxine exposure decreased placental expression of the serotonin transporter (SERT/Slc6a4) at the transcript and protein levels. In contrast, venlafaxine increased SERT expression in the hearts of female, but not male, fetuses. Expression of the serotonin 2B receptor (5-HT2B /Htr2b) and of fibroblast growth factor 8 was induced in fetal hearts. CONCLUSION: In utero venlafaxine exposure altered the placental index and induced fetal cardiac anomalies in rats. We propose that the increased incidence of cardiac anomalies is mediated through alterations in serotonin signaling in the placenta and fetal heart. Birth Defects Research (Part A), 2016. © 2016 Wiley Periodicals, Inc. Birth Defects Research (Part A) 106:1044-1055, 2016. © 2016 Wiley Periodicals, Inc.


Asunto(s)
Cardiopatías Congénitas/metabolismo , Corazón/efectos de los fármacos , Efectos Tardíos de la Exposición Prenatal/metabolismo , Inhibidores de Captación de Serotonina y Norepinefrina/efectos adversos , Serotonina/metabolismo , Clorhidrato de Venlafaxina/efectos adversos , Administración Oral , Animales , Femenino , Peso Fetal , Feto , Factor 8 de Crecimiento de Fibroblastos/genética , Factor 8 de Crecimiento de Fibroblastos/metabolismo , Expresión Génica/efectos de los fármacos , Corazón/fisiopatología , Cardiopatías Congénitas/inducido químicamente , Cardiopatías Congénitas/patología , Cardiopatías Congénitas/fisiopatología , Tamaño de la Camada , Masculino , Tamaño de los Órganos/efectos de los fármacos , Placenta/efectos de los fármacos , Embarazo , Efectos Tardíos de la Exposición Prenatal/inducido químicamente , Efectos Tardíos de la Exposición Prenatal/patología , Efectos Tardíos de la Exposición Prenatal/fisiopatología , Ratas , Ratas Sprague-Dawley , Receptor de Serotonina 5-HT2B/genética , Receptor de Serotonina 5-HT2B/metabolismo , Proteínas de Transporte de Serotonina en la Membrana Plasmática/genética , Proteínas de Transporte de Serotonina en la Membrana Plasmática/metabolismo , Transducción de Señal/efectos de los fármacos
15.
Br J Clin Pharmacol ; 82(3): 806-13, 2016 09.
Artículo en Inglés | MEDLINE | ID: mdl-27145452

RESUMEN

AIM: To describe biases in antimalarial randomized controlled trials (RCTs) during pregnancy and their influence on antimalarial drug efficacy to reduce the risk of low birth weight (LBW). METHODS: RCT characteristics and results were retrieved from a previous systematic review on the efficacy of antimalarials. The Cochrane risk of bias assessment was used to investigate source of biases in each RCT. The quality of RCT reporting published after the introduction of the CONSORT statement in medical literature in 1996 were compared to those published before 1996. A meta-regression analysis was performed to examine the impact of bias on the efficacy of antimalarials to reduce LBW after controlling for the time period prior to 1996. RESULTS: Twenty out of 25 RCTs (80%) had a high risk of bias. The proportion of RCTs having a low risk of bias was higher in manuscripts published after the introduction of CONSORT compared to those published before 1996 for sequence generation (P = 0.04) and allocation concealment (P = 0.04). Heterogeneity between RCTs was associated with an overestimation of the efficacy of antimalarial drugs in reducing LBW in RCTs with inadequate methods for randomization, allocation concealment or not being free of other bias. CONCLUSION: Antimalarial RCTs during pregnancy are poorly reported but may be improved by using the CONSORT statement. After taking into account the time period before 1996, we found that biases had an impact on the efficacy of antimalarials to reduce the risk of LBW.


Asunto(s)
Antimaláricos/uso terapéutico , Recién Nacido de Bajo Peso , Ensayos Clínicos Controlados Aleatorios como Asunto/normas , Sesgo , Femenino , Humanos , Embarazo , Proyectos de Investigación
16.
Br J Clin Pharmacol ; 81(4): 589-604, 2016 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-26613360

RESUMEN

AIMS: The aim of this study was to perform an up-to-date meta-analysis on the risk of cardiac malformations associated with gestational exposure to paroxetine, taking into account indication, study design and reference category. METHOD: A systematic review of studies published between 1966 and November 2015 was conducted using embase and MEDLINE. Studies reporting major malformations with first trimester exposure to paroxetine were included. Potentially relevant articles were assessed and relevant data extracted to calculate risk estimates. Outcomes included any major malformations and major cardiac malformations. Pooled odds ratios and 95% confidence intervals were calculated using random-effects models. RESULTS: Twenty-three studies were included. Compared with non-exposure to paroxetine, first trimester use of paroxetine was associated with an increased risk of any major congenital malformations combined (pooled OR 1.23, 95% CI 1.10, 1.38; n = 15 studies), major cardiac malformations (pooled OR 1.28, 95% CI 1.11, 1.47; n = 18 studies), specifically bulbus cordis anomalies and anomalies of cardiac septal closure (pooled OR 1.42, 95% CI 1.07, 1.89; n = 8 studies), atrial septal defects (pooled OR 2.38, 95% CI 1.14, 4.97; n = 4 studies) and right ventricular outflow track defect (pooled OR 2.29, 95% CI 1.06, 4.93; n = 4 studies). Although the estimates varied depending on the comparator group, study design and malformation detection period, a trend towards increased risk was observed. CONCLUSIONS: Paroxetine use during the first trimester of pregnancy is associated with an increased risk of any major congenital malformations and cardiac malformations. The increase in risk is not dependent on the study method or population.


Asunto(s)
Anomalías Inducidas por Medicamentos/etiología , Cardiopatías Congénitas/inducido químicamente , Exposición Materna/efectos adversos , Paroxetina/efectos adversos , Inhibidores Selectivos de la Recaptación de Serotonina/efectos adversos , Femenino , Humanos , Paroxetina/administración & dosificación , Paroxetina/uso terapéutico , Embarazo , Primer Trimestre del Embarazo , Medición de Riesgo , Inhibidores Selectivos de la Recaptación de Serotonina/administración & dosificación , Inhibidores Selectivos de la Recaptación de Serotonina/uso terapéutico
17.
CMAJ ; 188(10): 723-730, 2016 Jul 12.
Artículo en Inglés | MEDLINE | ID: mdl-27114489

RESUMEN

BACKGROUND: Isotretinoin, a teratogen, is widely used to treat cystic acne. Although the risks of pregnancy during isotretinoin therapy are well recognized, there are doubts about the level of adherence with the pregnancy prevention program in Canada. Our objective was to evaluate the effectiveness of the Canadian pregnancy prevention program in 4 provinces: British Columbia, Saskatchewan, Manitoba and Ontario. METHODS: Using administrative data, we identified 4 historical cohorts of female users of isotretinoin (aged 12-48 yr) for the period 1996 to 2011. We defined pregnancy using International Statistical Classification of Diseases and billing codes. One definition included only cases with documented pregnancy outcomes (high-specificity definition); the other definition also included individuals recorded as receiving prenatal care (high-sensitivity definition). We studied new courses of isotretinoin and detected pregnancies in 2 time windows: during isotretinoin treatment only and up to 42 weeks after treatment. Live births were followed for 1 year to identify congenital malformations. RESULTS: A total of 59 271 female patients received 102 308 courses of isotretinoin. Between 24.3% and 32.9% of participants received prescriptions for oral contraceptives while they were taking isotretinoin, compared with 28.3% to 35.9% in the 12 months before isotretinoin was started. According to the high-specificity definition of pregnancy, there were 186 pregnancies during isotretinoin treatment (3.1/1000 isotretinoin users), compared with 367 (6.2/1000 users) according to the high-sensitivity definition. By 42 weeks after treatment, there were 1473 pregnancies (24.9/1000 users), according to the high-specificity definition. Of these, 1331 (90.4%) terminated spontaneously or were terminated by medical intervention. Among the 118 live births were 11 (9.3%) cases of congenital malformation. Pregnancy rates during isotretinoin treatment remained constant between 1996 and 2011. INTERPRETATION: Adherence to the isotretinoin pregnancy prevention program in Canada was poor during the 15-year period of this study.


Asunto(s)
Anomalías Inducidas por Medicamentos/epidemiología , Acné Vulgar/tratamiento farmacológico , Anticoncepción/estadística & datos numéricos , Fármacos Dermatológicos/efectos adversos , Isotretinoína/efectos adversos , Resultado del Embarazo/epidemiología , Anomalías Inducidas por Medicamentos/prevención & control , Adolescente , Adulto , Canadá , Niño , Femenino , Humanos , Nacimiento Vivo/epidemiología , Persona de Mediana Edad , Embarazo , Estudios Retrospectivos , Adulto Joven
18.
Paediatr Perinat Epidemiol ; 30(6): 623-632, 2016 11.
Artículo en Inglés | MEDLINE | ID: mdl-27781295

RESUMEN

BACKGROUND: The 3D Cohort Study (Design, Develop, Discover) was established to help bridge knowledge gaps about the links between various adverse exposures during pregnancy with birth outcomes and later health outcomes in children. METHODS: Pregnant women and their partners were recruited during the first trimester from nine sites in Quebec and followed along with their children through to 2 years of age. Questionnaires were administered during pregnancy and post-delivery to collect information on demographics, mental health and life style, medical history, psychosocial measures, diet, infant growth, and neurodevelopment. Information on the delivery and newborn outcomes were abstracted from medical charts. Biological specimens were collected from mothers during each trimester, fathers (once during the pregnancy), and infants (at delivery and 2 years of age) for storage in a biological specimen bank. RESULTS: Of the 9864 women screened, 6348 met the eligibility criteria and 2366 women participated in the study (37% of eligible women). Among women in the 3D cohort, 1721 of their partners (1704 biological fathers) agreed to participate (73%). Two thousand two hundred and nineteen participants had a live singleton birth (94%). Prenatal blood and urine samples as well as vaginal secretions were collected for ≥98% of participants, cord blood for 81% of livebirths, and placental tissue for 89% of livebirths. CONCLUSIONS: The 3D Cohort Study combines a rich bank of multiple biological specimens with extensive clinical, life style, and psychosocial data. This data set is a valuable resource for studying the developmental etiology of birth and early childhood neurodevelopmental outcomes.


Asunto(s)
Trastornos del Neurodesarrollo/epidemiología , Efectos Tardíos de la Exposición Prenatal/epidemiología , Adolescente , Adulto , Escolaridad , Femenino , Humanos , Estilo de Vida , Masculino , Edad Materna , Persona de Mediana Edad , Ontario/epidemiología , Paridad , Embarazo , Atención Prenatal/estadística & datos numéricos , Quebec/epidemiología , Factores Socioeconómicos , Manejo de Especímenes/estadística & datos numéricos , Encuestas y Cuestionarios , Adulto Joven
19.
Arch Womens Ment Health ; 19(5): 835-43, 2016 10.
Artículo en Inglés | MEDLINE | ID: mdl-26957509

RESUMEN

Perinatal psychological stress has been associated with unfavorable maternal and neonatal outcomes. We aimed to assess the impact of perinatal stress on infant development at 1 year of age. We recruited pregnant women calling North American Teratogen Information Services or attending outpatient clinics at CHU Sainte Justine (Montreal) between 2008 and 2010 and their spouses. To be part of our study, women had to be (1) >18 years of age, (2) <15 weeks of gestational age at recruitment, (3) living within 250-km radius of Montreal, and (4) taking antidepressants or non-teratogenic drugs. Stress was assessed using the telephone-administered four-item perceived stress scale during pregnancy in mothers and at 2 months postpartum in both parents. Child development at 1 year of age was evaluated with the Bayley III scales. Socio-demographic and potential confounders were collected through telephone interviews. Multivariable linear regression models were built to assess the association between perinatal parental stress and child development. Overall, 71 couples and their infants were included. When adjusted for potential confounders, maternal prenatal stress was positively associated with motor development (adjusted ß = 1.85, CI 95 % (0.01, 3.70)). Postpartum maternal and paternal stresses were negatively associated with motor and socio-emotional development, respectively (adjusted ß = -1.54, CI 95 % (-3.07, -0.01) and adjusted ß = -1.67, CI 95 % (-3.25, -0.10), respectively). Maternal and paternal postnatal stress seems to be harmful for the motor and socio-emotional development in 1-year-old children. No association was demonstrated between parental stress and cognitive, language, and adaptive behavioral development. However, prenatal maternal stress appears to improve motor skills.


Asunto(s)
Antidepresivos/uso terapéutico , Desarrollo Infantil , Madres/psicología , Periodo Posparto , Estrés Psicológico/complicaciones , Adulto , Canadá , Femenino , Humanos , Lactante , Embarazo/psicología , Encuestas y Cuestionarios
20.
Birth Defects Res B Dev Reprod Toxicol ; 107(3): 136-47, 2016 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-27295407

RESUMEN

OBJECTIVE: To quantify the risk of major congenital malformations (MCMs) associated with the use of ovarian stimulators alone, intrauterine insemination (IUI), and assisted reproductive technologies (ARTs). METHODS: We conducted a case-control analysis using a birth cohort, built with the linkage of data obtained by a self-administered questionnaire, medical, pharmaceutic, and birth databases. Cases were pregnancies with at least one live birth with an MCM. Controls were pregnancies that did not result in major or minor congenital malformations. Multiple logistic regression models were used to calculate the odds ratios (ORs) and confidence intervals (CIs). RESULTS: Among the 5021 pregnancies identified, 825 were cases of MCM and 4196 were controls. Compared with spontaneous conception, the use of ART increased the risk of major urogenital malformations (adjusted OR, 3.11; 95% CI, 1.33-7.27). The use of IUI was associated with an increased risk of major musculoskeletal malformations (adjusted OR, 2.02; 95% CI, 1.10-3.71). Among the 471 women who used fertility treatments for conception, the use of ART was associated with an increased risk of any MCM (adjusted OR, 1.66; 95% CI, 1.00-2.79) and urogenital malformations (adjusted OR, 7.18; 95% CI, 1.59-32.53) when compared with ovarian stimulators used alone. CONCLUSIONS: The use of ART and IUI was associated with an increased risk of major musculoskeletal and urogenital malformations. ART was associated with a higher risk of MCM compared to ovarian stimulators used alone. Even the adjustment, a contribution of the underlying subfertility problems cannot completely ruled out given the differences in the severity of subfertility.


Asunto(s)
Anomalías Congénitas/etiología , Fertilización In Vitro/efectos adversos , Inseminación , Inducción de la Ovulación , Técnicas Reproductivas Asistidas/efectos adversos , Adolescente , Adulto , Índice de Masa Corporal , Estudios de Casos y Controles , Femenino , Humanos , Estilo de Vida , Modelos Logísticos , Factores de Riesgo , Factores Socioeconómicos , Resultado del Tratamiento , Adulto Joven
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA